Blood test may unlock secrets of drug resistance in lung cancer

NCT ID NCT04087473

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study analyzed blood samples from 50 adults with advanced ALK-positive lung cancer whose disease had stopped responding to one or two ALK inhibitors. The goal was to identify genetic changes in the cancer that cause drug resistance. By matching these changes to the right next treatment, doctors hope to improve outcomes for patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If successful, this could help doctors choose the right targeted therapy for patients whose lung cancer has stopped responding to current ALK inhibitors.
What could go wrong
This is a small, completed observational study (50 people) that looked at blood samples, not a treatment trial. The findings may not apply to all patients or lead to immediate changes in care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALK-POSITIVE LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Asan Medical Centre

    Seoul, 05505, South Korea

  • National Cancer Center Singapore

    Singapore, 169690, Singapore

  • Seoul National University Hospital

    Seoul, South Korea

  • The Chinese University of Hong Kong

    Hong Kong, Hong Kong

  • University Malaya Medical Centre

    Kuala Lumpur, Malaysia

More trials for these conditions

Other studies related to the condition(s) this trial covers.